LG 100268 – 5 mg

Brand:
Cayman
CAS:
153559-76-3
Storage:
-20
UN-No:
Non-Hazardous - /

LG 100268 is an agonist of retinoid X receptors (RXRs; Kd = 3 nM).{20758} It is selective for RXRs over retinoic acid receptors (RARs; Kd = >10,000 nM).{36450} In vitro, LG 100268 (1 µM) induces apoptosis in HL-60 human leukemia cells when used in combination with TTNPB (Item No. 16144).{20758} LG 100268 (100, 300, and 1,000 nM) dose-dependently inhibits COX-2 expression and increases ATP-binding cassette transporter (ABCA1) levels in macrophage-like RAW 264.7 cells.{36451} In vivo, it inhibits vinyl carbamate-induced lung tumor growth in mice when administered at a dose of 40 mg/kg.  

 

Out of stock

SKU: 21606 - Category:

Description

An RXR agonist (Kd = 3 nM); selective for RXRs over RARs (Kd = >10,000); induces apoptosis in HL-60 human leukemia cells when used at a concentration of 1 µM in combination with TTNPB; dose-dependently inhibits COX-2 expression (100, 300 and 1000 nM) and increases ABCA1 levels in macrophage-like RAW 264.7 cells; inhibits vinyl carbamate-induced lung tumor growth in mice (40 mg/kg)


Formal name: 6-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)cyclopropyl]-3-pyridinecarboxylic acid

Synonyms:  AGN 192620|CD3127

Molecular weight: 363.5

CAS: 153559-76-3

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Endocrinology & Metabolism|Hormones & Receptors|RARs, RORs, & RXRs||Research Area|Immunology & Inflammation|Innate Immunity